Diabetes
Welcome to MassDevice's Diabetes Hub, your resource for the latest news in diabetes technology. Stay informed about the innovations and business news shaping the diabetes device industry.
Here are top diabetes features from MassDevice and its sister publications (and scroll down to read the latest diabetes device news from MassDevice):
+ The 9 largest diabetes tech companies in the world
+ These diabetes devices are set to launch in 2024
+ The biggest stories from the American Diabetes Association (ADA) 2024 Scientific Sessions
+ These diabetes devices are set to launch in 2024
+ How Dexcom designed a new “life-changing” sensor for even more people with diabetes
+ Embecta CEO sees GLP-1 opportunities as company progresses on insulin patch pump
Latest Diabetes News
Intarcia adds $225m for Type II diabetes trial
Intarcia Therapeutics yesterday took its total raise to more than $1 billion with a $225 million funding round it plans to use to run clinical trials and commercialize its the drug-device combination treatment it’s developing for Type II diabetes.
Diabetes: WPI to run pilot study on foot ulcer app
Researchers connected with Worcester Polytechnic Institute and the UMass. Medical School are gearing up to run a pilot study on a new smartphone app that tracks the progress of foot ulcers in diabetics.
Diabetes: DreaMed licenses artificial pancreas tech to Medtronic
Medtronic buys Dutch diabetes clinic
Diabetes: Asante Solutions withdraws IPO
Asante Solutions withdrew its plans for an initial public offering it had hoped would bring in $49 million for its Snap modular insulin pump.
FDA requiring warning label for multi-dose diabetes pen devices
By David Lennarz, Vice President and Co-Founder of Registrar Corp
Diabetes: Valeritas delays $75m IPO
Valeritas today postponed its planned initial public offering, which at the midpoint was slated to fetch $75 million for its V-Go basal insulin delivery system for Type II diabetes, Renaissance Capital reported.
Earlier this month Valeritas said it planned to put up 5 million shares at $14 to $16 each.
Diabetes: Medtronic joins $44m round for Semma Therapeutics
Diabetes: Medtronic gets in on $17m Series B for Glooko
Diabetes: Valeritas sets terms for $75m IPO
Valeritas yesterday set the terms for its forthcoming initial public offering, saying it plans to put up 5 million shares at $14 to $16 each.
At the midpoint of the range, the IPO would fetch $75 million for Bridgewater, N.J.-based Valeritas, which plans to list on the NASDAQ exchange under the "VLRX" symbol.
